These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22472995)

  • 1. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.
    Dooley KE; Bliven-Sizemore EE; Weiner M; Lu Y; Nuermberger EL; Hubbard WC; Fuchs EJ; Melia MT; Burman WJ; Dorman SE
    Clin Pharmacol Ther; 2012 May; 91(5):881-8. PubMed ID: 22472995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I.
    Keung A; Reith K; Eller MG; McKenzie KA; Cheng L; Weir SJ
    Int J Tuberc Lung Dis; 1999 May; 3(5):426-36. PubMed ID: 10331733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
    Dooley KE; Savic RM; Park JG; Cramer Y; Hafner R; Hogg E; Janik J; Marzinke MA; Patterson K; Benson CA; Hovind L; Dorman SE; Haas DW;
    Antimicrob Agents Chemother; 2015; 59(6):3399-405. PubMed ID: 25824215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects.
    Winter H; Egizi E; Murray S; Erondu N; Ginsberg A; Rouse DJ; Severynse-Stevens D; Pauli E
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1219-24. PubMed ID: 25512422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
    Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
    J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single and multiple dose pharmacokinetics of rifapentine in man: part II.
    Keung A; Eller MG; McKenzie KA; Weir SJ
    Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
    Dooley K; Flexner C; Hackman J; Peloquin CA; Nuermberger E; Chaisson RE; Dorman SE
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4037-42. PubMed ID: 18765687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.
    Keung AC; Owens RC; Eller MG; Weir SJ; Nicolau DP; Nightingale CH
    Antimicrob Agents Chemother; 1999 May; 43(5):1230-3. PubMed ID: 10223941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction.
    Keung AC; Eller MG; Weir SJ
    J Clin Pharmacol; 1998 Jun; 38(6):517-24. PubMed ID: 9650541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
    Savic RM; Lu Y; Bliven-Sizemore E; Weiner M; Nuermberger E; Burman W; Dorman SE; Dooley KE
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3035-42. PubMed ID: 24614383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
    Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
    Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.
    Townsend R; Dietz A; Hale C; Akhtar S; Kowalski D; Lademacher C; Lasseter K; Pearlman H; Rammelsberg D; Schmitt-Hoffmann A; Yamazaki T; Desai A
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):44-53. PubMed ID: 27273461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose pharmacokinetics of rifapentine in elderly men.
    Keung AC; Eller MG; Weir SJ
    Pharm Res; 1998 Aug; 15(8):1286-91. PubMed ID: 9706063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
    Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
    Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
    Mohamed MF; Jungerwirth S; Asatryan A; Jiang P; Othman AA
    Br J Clin Pharmacol; 2017 Oct; 83(10):2242-2248. PubMed ID: 28503781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.